NCT02305446View on ClinicalTrials.gov

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
BIOLOGICAL

Meningococcal (group B) multicomponent recombinant adsorbed vaccine

One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.

Trial Locations (1)

Unknown

01, Novartis Investigational Site, Krakow

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT02305446 - Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ. | Biotech Hunter | Biotech Hunter